Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Objective: To investigate the association between hypothyroidism and cardiovascular disease (CVD) in both treated and untreated hypothyroid patients, and the consequences of over- and under-treatment with respect to cardiovascular risk. Design: A registry-based case–control study nested within a population-based cohort of 275 467 individuals with at least one serum thyroid stimulating hormone (TSH) measurement in the period of 1995–2011. Methods: Incident cases of CVD were matched with controls according to gender, age and year of birth. Conditional logistic regression analyses were performed to calculate CVD risks associated with exposure to hypothyroidism, with adjustment for 19 pre-existing comorbidities, including cardiovascular disease and diabetes, using the Charlson Comorbidity Index. Results: Overall, 20 487 individuals experienced CVD (9.4%, incidence rate 13.1 per 1000 person-years, 95% confidence interval (CI), 13.0–13.3). Risk of CVD was increased in untreated hypothyroidism compared to euthyroidism (odds ratio (OR): 1.83 (95% CI: 1.43–2.35;P < 0.001)). Cardiovascular risk was increased in both treated and untreated hypothyroid individuals per half year of elevated TSH (OR: 1.11 (95% CI: 1.06–1.16;P < 0.001) and OR: 1.15 (95% CI: 1.09–1.23;P = 0.001), respectively). In patients treated with levothyroxine, OR for CVD was 1.12 (95% CI: 1.06–1.18;P < 0.001) for each 6 months of decreased TSH. Conclusion: Cardiovascular risk is increased in untreated, but not in treated hypothyroid patients. Among those with treated hypothyroidism, duration of decreased TSH (overtreatment) had a similar impact on cardiovascular risk as duration of elevated TSH (under-treatment), highlighting the importance of initiating treatment and maintaining biochemical euthyroidism in hypothyroid patients in order to reduce the risk of CVD and death.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a recent retrospective cohort study 71 that included 20 724 older primary care patients taking levothyroxine, 34% had thyrotropin levels below the reference range, which was more frequent in women than in men (36.7% vs 23.9%, respectively).”
From Hypothyroidism: A Review (2025) · cites this paper as [71]
In the citing paper
“as the use of supratherapeutic doses of LT4, can result in cardiac and bone toxicity, as well as being associated with an increased risk of mortality.[12][13][14]”
From Refractory hypothyroidism: unraveling the complexities of diagnosis and management (2023) · cites this paper as [13]
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
The Danish National Patient Registry: a review of content, data quality, and research potential
Schmidt, M., Schmidt, S. A. J., Sandegaard, J. L., Ehrenstein, V., Pedersen, L., & Sørensen, H. T. (2015) · Clinical Epidemiology · doi:10.2147/clep.s91125 · Cited by 4,769
Vandenbroucke, J. P., von Elm, E., Altman, D. G., Gøtzsche, P. C., Mulrow, C. D., Pocock, S. J., Poole, C., Schlesselman, J. J., & Egger, M. (2007) · Epidemiology · doi:10.1097/ede.0b013e3181577511 · Cited by 2,779
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
The Danish Register of Causes of Death
Helweg-Larsen, K. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811399958 · Cited by 1,732
Data Resource Profile: The Danish National Prescription Registry
Pottegård, A., Schmidt, S. A. J., Wallach-Kildemoes, H., Sørensen, H. T., Hallas, J., & Schmidt, M. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw213 · Cited by 1,431
Subclinical Hypothyroidism and the Risk of Coronary Heart Disease and Mortality
Rodondi, N., den Elzen, W. P. J., Bauer, D. C., Cappola, A. R., Razvi, S., Walsh, J. P., Åsvold, B. O., Iervasi, G., Imaizumi, M., Collet, T.-H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1361 · Cited by 1,216
2013 ETA Guideline: Management of Subclinical Hypothyroidism
Pearce, S. H. S., Brabant, G., Duntas, L. H., Monzani, F., Peeters, R. P., Razvi, S., & Wemeau, J.-L. (2013) · European Thyroid Journal · doi:10.1159/000356507 · Cited by 877
Subclinical thyroid dysfunction as a risk factor for cardiovascular disease
Walsh, J. P., Bremner, A. P., Bulsara, M. K., O’Leary, P., Leedman, P. J., Feddema, P., & Michelangeli, V. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.21.2467 · Cited by 536
Goldstein, B. I., Carnethon, M. R., Matthews, K. A., McIntyre, R. S., Miller, G. E., Raghuveer, G., Stoney, C. M., Wasiak, H., & McCrindle, B. W. (2015) · Circulation · doi:10.1161/cir.0000000000000229 · Cited by 519
Cited by
2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management
Durante, C., Hegedüs, L., Czarniecka, A., Paschke, R., Russ, G., Schmitt, F., Soares, P., Solymosi, T., & Papini, E. (2023) · European Thyroid Journal · doi:10.1530/etj-23-0067 · Cited by 425
“In the absence of elevated TSH, the use of thyroid hormone in order to decrease TSH should be discouraged in order to limit the increased morbidity and mortality seen with such therapy (101, 102), but mainly because of its lack of efficacy in adequately decreasing size in symptomatic nodules (103).”
BackgroundSelf-citationChaker, L., Razvi, S., Bensenor, I. M., Azizi, F., Pearce, E. N., & Peeters, R. P. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00357-7 · Cited by 330
Orloff, L. A., Noel, J. E., Stack, B. C., Russell, M. D., Angelos, P., Baek, J. H., Brumund, K. T., Chiang, F., Cunnane, M. B., Davies, L., et al. (2022) · Head & Neck · doi:10.1002/hed.26960 · Cited by 315
Self-citationHashimoto thyroiditis: an evidence-based guide: etiology, diagnosis and treatment
Klubo-Gwiezdzinska, J., & Wartofsky, L. (2022) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16222 · Cited by 207
Optimal thyroid hormone replacement
Jonklaas, J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab031 · Cited by 89
Metadata
- Authors
- Lillevang-Johansen, M., Abrahamsen, B., Jørgensen, H. L., Brix, T. H., & Hegedüs, L.
- Affiliations
- 1Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
- University of Southern Denmark (DK)
- University of Copenhagen (DK)
- Odense University Hospital (DK)
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-06
- Volume
- 180
- Issue
- 6
- Pages
- 407-416
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2942897736
- Cited by
- 100
- References
- 49
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 22 · 2023: 14 · 2022: 19 · 2021: 14 · 2020: 2 · 2019: 4
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- hypothyroidism, cardiovascular disease, overtreatment, undertreatment, thyroid-stimulating hormone, levothyroxine, thyroid hormone replacement, euthyroidism, cardiovascular risk, thyroid function monitoring
- MeSH terms
- Medical Overuse, Adult, Aged, Cardiovascular Diseases, Female, Health Services Misuse, Humans, Hypothyroidism, Male, Middle Aged, Registries, Risk Factors, Time Factors, Cohort Studies, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk. https://app.cochat.ai/papers/10.1530/eje-19-0006
- The paper
- Lillevang-Johansen, M., Abrahamsen, B., Jørgensen, H. L., Brix, T. H., & Hegedüs, L. (2019). Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk. European Journal of Endocrinology. https://doi.org/10.1530/eje-19-0006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.